Gain Therapeutics, Inc.GANXEarnings & Financial Report
Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineere...
GANX Q3 FY2024 Key Financial Metrics
Revenue
$105.4K
Gross Profit
N/A
Operating Profit
$-4.5M
Net Profit
$-4.5M
Gross Margin
N/A
Operating Margin
-4230.3%
Net Margin
-4255.7%
YoY Growth
N/A
EPS
$-0.17
Gain Therapeutics, Inc. Q3 FY2024 Financial Summary
Gain Therapeutics, Inc. reported revenue of $105.4K for Q3 FY2024, with a net profit of $-4.5M (up 4.9% YoY) (-4255.7% margin).
Key Financial Metrics
| Total Revenue | $105.4K |
|---|---|
| Net Profit | $-4.5M |
| Gross Margin | N/A |
| Operating Margin | -4230.3% |
| Report Period | Q3 FY2024 |
Gain Therapeutics, Inc. Quarterly Revenue & Net Profit History
Gain Therapeutics, Inc. results over the last 3 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2024 | $105.4K | — | $-4.5M | -4255.7% |
| Q2 FY2024 | $84.5K | — | $-8.1M | -9633.2% |
| Q1 FY2024 | $115.3K | +109.0% | $-4.0M | -3481.4% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|
| Revenue | $115303 | $84531 | $105405 |
| YoY Growth | 109.0% | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|
| Assets | $14.6M | $19.2M | $14.4M |
| Liabilities | $5.9M | $7.4M | $5.5M |
| Equity | $8.6M | $11.8M | $8.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | |
|---|---|---|---|
| Operating CF | $-3.6M | $-5.8M | $-6.1M |